Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Amrecibart · REGN-9933

Monoclonal antibody · Inhibitor of Coagulation factor XI (F11) · developed by REGENERON PHARMACEUTICALS

Phase 3 Most advanced trial
REGN Developer
1 Registered trials

What is Amrecibart?

Amrecibart is an antibody that binds the apple 2 (A2) domain of coagulation factor XI and its activated form, FXIa. By preventing intrinsic pathway-triggered FXI activation, it inhibits contact activation-initiated blood coagulation and thrombus formation. It is being studied in peripheral artery disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
REGN-9933
Drug type
Monoclonal antibody
Targets
Coagulation factor XI (F11)
Mechanism
Inhibitor of Coagulation factor XI (F11)
Pathways
intrinsic coagulation pathway, contact activation-initiated blood coagulation, thrombus formation
Therapy area
Cardiovascular
Developer
REGENERON PHARMACEUTICALS (REGN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
ZDR9VW2WMN

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07318610 Phase 3 Peripheral Artery Disease (PAD) Recruiting REGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Peripheral Artery Disease (PAD)

Other drugs acting on F11

More from REGENERON PHARMACEUTICALS

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the REGN page.

Follow REGN, the company behind Amrecibart

See REGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

REGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.